GenMark Diagnostics traded at $24.04 this Wednesday April 21st, decreasing $0 or 0 percent since the previous trading session. Looking back, over the last four weeks, GenMark Diagnostics lost 0.17 percent. Over the last 12 months, its price rose by 169.66 percent. Looking ahead, we forecast GenMark Diagnostics to be priced at 23.37 by the end of this quarter and at 21.49 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

GenMark Diagnostics
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company is focused on developing and commercializing its eSensor detection technology. The Companys electrochemical technology enables detection of up to 72 distinct biomarkers in a single sample. The Companys XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with workstation and self-contained, disposable test cartridges. The Company also developed two hepatitis C virus (HCV), genotyping tests, a 3A4/3A5 genotyping test and a 2C19 genotyping test, versions of which are available for research use only (RUO). The Companys products include XT-8 System, XT-8 Test Menu, Vitro Diagnostic (IVD) Test Menu and Research Use Only (RUO) Test Menu. The Companys technologies include XT-8 eSensor Technology, XT-8 Test Cartridges and XT-8 Workstation.